Identification of a novel transthyretin variant (Val30→Leu) associated with familial amyloidotic polyneuropathy  by Nakazato, Masamitsu et al.
Volume 306, number 2,3, 206-208 FEBS 11311 
© 1992 Federation of European Biochemical Societies 00145793/92/$5.00 
July 1992 
Identification of a novel transthyretin variant (Val3°- Leu) associated 
with familial amyloidotic polyneuropathy 
Masamitsu Nakazato"', Shu-ichi Ikeda b, Kazutaka Shiomi '~, Shigeru Matsukura ", Kunihiro Yoshida b, 
Hideaki Shimizu °, Tetsushi Atsumi ~, Kenji Kangawa 'j and Hisayuki Matsuo ~" 
Departments of ~Medicine attd aBiochemistry, Miya:afci Medical College, Kiyotake, Miya',aki 889-16, Japan, bDepartment of
Medicine (Neurology), Stt#zshtt University School of Medicine, Matsumoto, Nagano 390, Japan, ~Seirei Hamamatsu General 
Hospital, Hamamatsu 430, Japan and "NaHonal Cardiot,asctdar Center Research Institute, SMta 365, Osalca, Japan 
Received 12 May 1992; revised version received 28 May 1992 
A novel variant ransthyretln which contains a leucine+for.valine substitution at position 30 was isolated and identified in the serum of a patient 
with familial amyloidotic polyneuropathy (FAP). The amino acid substitution was proven to result from a guanine.to-c~,,tosine change at the first 
base of codon 30 located in exon 2 in the mutated transthyretin gene by restriction fi'agment length uriah'sis on the amplified transthyretin gene 
using Cfrl3 1. The study indicates that the point mutation o1" the transthyl'etin gene is a cause of the disorder. 
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1. INTRODUCTION 
Familial amyloidotic polyneuropathy (FAP) is an 
autosomal dominant~ inherited disorder with systemic 
deposition of amyloid fibrils. Clinically, FAP is charac- 
terized by progressive sensory, autonomic, and motor 
polyneuropathy followed by fatal cardiac and renal fail- 
ure [1]. Recent biochemical and molecular biological 
studies [2] have showo FAP to be a molecular disorder 
of transthyretin (also called prealbumin). The major 
protein constituent of FAP amyl0id is a variant trans- 
thyretin wlaich has one amino acid substitution resulting 
from one base change on the transthyretin gene. In type 
I FAP, the most widespread form of FAP, amyloid 
protein consists of a variant transthyretin with a 
methionine-for-valine substitution at position 30 [3-5]. 
We have studied a Japanese pat ient  exhibit ing symp- 
toms of type 1 FAP .  We identif ied a novel posit ion 30 
mutat ion  in a var iant  t ransthyret in ,  being distinct fi'om 
the methionine subst i tut ion.  We also analyzed the trans- 
thyret in gene to find the base change causing the amino  
acid subst i tut ion.  
2. MATERIALS  AND METHODS 
2.1. Purification of serum transth),retin 
Five ml of the serum was obtained from a 53-year-old Japanese 
woman with FAP. She gradaalb' developed ysesthesia in the legs at 
age 50, with subsequent progressive s nsorimotor polyneuropathy and 
Correspondence address: M. Nakazato, Third Department of Internal 
Medicine, Miyazaki Medical College. 5200 Kiyotakg, Miyazaki 889- 
16, Japan. Fax: (81) (985) 85-6503. 
various autonomic dysfunctions including periodic severe anorexia 
and nausea. Her rectal and sural nerve biopsie~ revealed amyloid 
deposits which were specifically stained by anti.human transthyretin 
antiserum. Her serum was loaded on an Affi-Gel Blue resin column 
(1.5 × ')-5 cm, BioRad) pre-equilibrated with the above phosphate 
buffer as reported elsewhere [6]. Unretained IYactions were subjected 
to immunoaffinity chromatography on an anti-transthyretin legAl'fi- 
Gel 10 column (0.8 × 6 era, BioRad). After the column was washed 
with 50 mM sodium phosphate buffer (pH 7.4), bound transthyretin 
was eluted with 3 ml of 1% diethyl amine solution, "rransthyretin was 
finally purified as a single peak by reverse.phase high performance 
liquid chromatography (HPLC) on a TSK ODS-Phenyl 5PW-RP col- 
umn (4.6 × 25 ram, Tosoh Co. Ltd.). A linear gradient ofacetonitrile 
(CHsCN) from 10% to 60% in 0.1% trifluoroacetie acid (TFA) was 
employed for 40 rain at a flow rate of 1.0 ml/min. 
2.2. Am01o acM sequence at~alysis 
One-halfofthe purified serum transthyrctin was treated with trypsin 
in 0.1 M Tris-HCI buffer (pH 8.0) for 2 h, and the resulth~ 8 peptiden 
were analyzed by reverse-phase HPLC on a TSK ODS SIL 120 A 
column (4.6 x 250 ram, Tosob), A linear gradient of CH3CN l'ron~. 0% 
to 60% in 0.1% TFA was employed for 60 rain at a rate of 1.0 ml/min. 
Tryptic peptides of' normal human transthyretin were al~o analyzed 
by the same HPLC system. Sequence analysis was performed by a 
model 470A protein sequencer linked on-line to a model 120A PTH 
analyzer (Applied Biosystems). PTH-amino acids were measurable at
concentrations as low as 0.5 pmol. and 5 pmol of a standard PTH- 
anaino acid mixture (Pierce) was routinely used as a calibration mix. 
tare .  
2.3. Transthyretit~ gene attalysls 
Total genomic DNA was isolated from the patient's peripheral 
blood leucocytes and from those of normal individuals. A 368 base 
pairs (bp) subsequenee of the transthyretin gene including exon 2 was 
amplified with 2 kinds or 24 baze oligonueleotide primers (5'. 
ATTGTCGACACTTACGTTCCTGAT.3' and 5'-TGTAAATTCT- 
TTAGCAGATGATGT-Y) using Gene Amp PeR kit (Perkin Elmer 
Cetus). Amplified DNA was digested with endonuclease Cfrl3 1 
(TaKaRa Shuzo Co. Ltd.), and the resulting DNA fl'agments were 
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¢leetrophoresed through 3% Nusiev¢ 3:1 A~rose gel (FMC BioPro- 
ducts). 
3. RESULTS AND DISCUSSION 
Serum transthyretin was efficiently purified by three- 
step chromatography. The amino acid sequence of the 
patient's erum transthyretin was determined by com- 
paring its tryptic peptide map with that of normal 
human transthyretin asshown in Fig. 1. One extra pep- 
tide, peak T-4*, was observed in the patient's map. On 
the other hand, the T-4 peak area of the patient's trans- 
thyretin was decreased to 60% of that in normal trans- 
thyretin. Amino acid sequences of peptides T-4 and 
T-4* were determined with 100 pmol of each peptide by 
an automated gas-phase sequencer. Peptide T-4 was 
confirmed to correspond to the region (residues 22-34) 
of normal transthyretin. The amino acid sequence or 
peptide T-4* was determined to be: Gly.Ser-Pro.Ala- 
Ile.Asn-Val.Ala.Leu.His-Val.Phe.Arg, in which a leuc- 
ine as the ninth amino acid residue was substituted for 
a valine in Oeptide T-4 from normal tr.~nsthyretin. All
the tryptic peptides except T-4* from the patient's trans- 
thyretin were observed at the same positions as those of 
the control on reverse phase HPLC. Thus, the trans- 
thyretln was clarified to be a variant ransthyretin with 
a leucine-for-valine substitution at position 30. The 
ratio of T-4 and T-4* in the patient's map was 3:2, 
indicating that the patient's erum transthyretin con- 
sisted of a mixture of normal and the variant trans- 
thyretin. The relatively low ratio of T-4* in comparison 
to T-4 is probably due to anayloid deposition of the 
variant ransthyretin  tissue. 
The leucine-for-valine substitution can be ascribed to 
the change of GTG to CTG in codon 30 of the trans- 
thyretin gene. This mutation creates a new cleavage site 
for Cfrl3 I (GGCCG--->GGCCC), yielding two frag- 
ments of length 156 and 212 bps. After digestion with 
this endonuclease, the patient's DNA showed two extra 
bands of 156 and 212 bps in addition to a normal band 
of 368 bps (Fig. 2), indicating the presence of G--->C 
transversion i the mutatec2 transthyretin gene as shown 
in Fig. 3. This result shows that DNA diagnosis of the 
patients and carriers of the PAP can be done using 
restriction fragment length analysis on the amplified 
transthyretin gene. 
Transthyretin is a stable and symmetrical tetramer 
composed of four identical subunits of 14 kDa. A trans- 
thyretin molecule has extensive fl-sheet structure with 
monomers having eight p-strands [7]. This characteris- 
tic conformation is thought o predispose toward amy- 
loid fibril formation, sometimes causing senile systemic 
amyloidosis by normal transthyretin i  normal-aged in- 
dividuals [8]. A conformational modification produced 
by an amino acid substitution would lead to more for- 
mation of amyloidogenic conformation i  the variant 
transthyretin molecule. More than 15 kinds of variant 
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Fig. 1. HPLC profile oftryptic peptides from (A) normal serum trans- 
thyretin and (B) patient's erum transthyretin. Trypti¢ diggsts were 
applied to a column ofTSK ODS SIL 120A (4.6 x 250 mm) and eluted 
with a linear gradieat of CH~CN (0-60%) in 0. 1% TFA for 60 rain at 
a flow rate of 1.0 ml/mln. 
transthyretins have been found in FAP of different eth- 
nic origins. Four variant ransthyretins are know~= to be 
involved in hereditary amyloid cardiomyopathy, and 
rout. others are apparently non-amyloidogenic [9]. The 
patient studied here had amyloid deposits in the rectum 
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Fig. 2. Analysis patterns ofamplificd transthyretin DNA digcstgl with 
Cfrl3 1. (Lane I) Non-dighted patient's DNA; (1') digested patient's 
DNA; (2) non-digested control DNA: (2') digested control DNA; (M) 
I kb DNA Ladder (Gibco BRL Life Tgchnolosies Inc.). 
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normal  Va l  A la  Va l  His  
t raanth) , ret in  gene  - - - G T G G C C G T G C A T - - - 
1 
mutated  Va l  A la  beu HI~ 
. . . .  GTGGCC .CTGCAT - - -  tramthyretin gone I I 
Cfrl3 I 
Fig. 3. Partial amino acid and nucleotide sequences ofLea a° variant 
transtl'l),retin, A new cleavage site (GGCCC) for Cj?13 I is produced 
in the mutated transthyretin gene. 
and sural nerve which were confirmed by alkaline 
Congo-red staining. The amyloids were specifically 
stained by anti-human transthyretin antiserum. Thus, 
the leueine-for-valine substitution is concluded to be a 
pathogenic one, not a polymorphic substitution. 
Leucine at position 30 identified in this study is the 
third mutation at the position found to be associated 
with FAP. A methionine-for-valine substitution at posi- 
tion 30 has been found in type I FAP, the subclass of  
FAP most widely distributed throughout the world [3- 
5]. An alanine-for-valine substitution at the same posi- 
tion was reported in FAP  of German origin [10]. These 
three types of FAP  with different amino acid substitu- 
tions have remarkably similar clilfical manifestations. 
Valine-30 is situated at the beginning of  one ,8-strand0 
being placed into the subunit core located between the 
two fl-sheets. The alteration to hydrophobic amino 
acids at the position would favor aggregation and amy- 
loid fibril formation of  variant molecules, causing clini- 
cal development of FAP. 
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